BACKGROUND: The primary treatment for head and neck @entity2347 ( @entity2347 ) is surgery. Infrequently, however, @entity2347 's propensity for perineural and base of skull invasion can preclude definitive surgical management. We present our experience with proton @entity1161 ( @entity1161 ) and concurrent @entity902 -based chemotherapy. METHODS: Nine @entity1 with unresectable node-negative, nonmetastatic head and neck @entity2347 received @entity1161 and concurrent @entity900 . Outcomes and @entity137 were recorded. A systematic review of the literature was performed. RESULTS: Median follow-up was 27 months (range, 9.2-48.3 months). Four @entity1 achieved complete response at the primary site, and an additional 4 @entity1 achieved stabilization of @entity66 . Only 1 @entity1 developed @entity66 progression. Four @entity1 had 5 acute grade 3 (G3) @entity137 , and 1 @entity1 developed a chronic G4 @entity1781 . CONCLUSION: Our preliminary results suggest @entity1161 and concurrent chemotherapy is a definitive treatment option for select @entity1 with head and neck @entity2347 .    2015 Wiley Periodicals, Inc. Head Neck 38: E1472-E1480, 2016.

Definitive proton @entity1161 and concurrent XXXX for unresectable head and neck @entity2347 : A series of 9 cases and a critical review of the literature.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity66 :: ('MESH:D004194', 'Disease') :: ['local disease'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['definitive proton RT', 'radiation therapy', 'RT', 'proton RT'] @entity2347 :: ('MESH:D003528', 'Disease') :: ['adenoid cystic carcinoma', 'ACC'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1781 :: ('MESH:D009901', 'Disease') :: ['optic nerve disorder'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
